The Drug Discovery Hackathon 2020 (DDH2020) vision and mission is to establish an “open innovation model” for in silico drug discovery against COVID-19 and will cover the various processes in drug discovery including, but not limited to, in silico screening of molecules, lead optimization and identification of druggable non-toxic targets. The targets, tools or lead molecules identified through the process of DDH2020 will be taken forward for synthesis followed by subsequent steps in a routine drug discovery program.
As an active supporter of the scientific community worldwide that is collaborating on COVID-19 solutions, Dassault Systèmes has developed BIOVIA Discovery Studio. This world-class life sciences modeling and simulation environment brings together over 30 years of peer-reviewed research and in silico technique. It provides researchers with a complete toolset for use, from target identification through lead optimization including tools for biologics design and analysis, classical simulations, structure- and fragment-based design, virtual ligand screening, as well as ADME (Absorption, Distribution, Metabolism, Excretion) and toxicity prediction.